首页> 美国卫生研究院文献>Journal of Medical Case Reports >Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: A case report
【2h】

Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: A case report

机译:下颌骨坏死是每年双膦酸盐治疗骨质疏松症的一种可能的罕见副作用:病例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionOsteonecrosis of the jaw is a serious side effect in patients receiving nitrogen-containing bisphosphonates intravenously due to malignant diseases. Albeit far less frequently, osteonecrosis of the jaw has also been reported to occur due to the oral administration of nitrogen-containing bisphosphonates due to osteoporosis. Annual infusions of zoledronic acid have been recommended in order to improve patient compliance, to optimize therapeutic effects and to minimize side effects. To date, osteonecrosis of the jaw has not been linked to the annual administration of bisphosphonates.
机译:简介由于恶性疾病,静脉内注射含氮双膦酸盐的患者下颌骨坏死是严重的副作用。尽管由于骨质疏松症而口服含氮的双膦酸盐,但据报道颌骨坏死的发生频率也要低得多。为了改善患者依从性,优化治疗效果并使副作用最小化,建议每年注射唑来膦酸。迄今为止,颌骨坏死尚未与双膦酸盐的年度给药有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号